Evidence map›Paper›PMID 39582862›Full record

ArticleFrontiers in immunology2024

Case report: Successful remission with upadacitinib in a young patient with anti-TNF-refractory intestinal Behçet's disease.

Sumei Sha, Bin Xu, Kairuo Wang, Chenyang Qiao, Haitao Shi, Jiong Jiang, Xiaojing Quan, Xin Liu

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Management of Severe Behçet's Disease.Current rheumatology reports · 2026
    Review
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Sumei ShaDepartment of Gastroenterology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.
Bin XuDepartment of Radiotherapy, Tangdu Hospital of the Air Force Medical University, Xi'an, Shaanxi, China.
Kairuo WangDepartment of Gastroenterology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.
Chenyang QiaoDepartment of Gastroenterology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.
Haitao ShiDepartment of Gastroenterology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.
Jiong JiangDepartment of Gastroenterology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.
Xiaojing QuanDepartment of Gastroenterology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.
Xin LiuDepartment of Gastroenterology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The limited therapeutic options and inconsistent treatment efficacy of Intestinal Behçet's disease complicate its management, with the absence of standardized guidelines further exacerbating the challenges faced by clinicians. Case Presentation: In this case report, we present a patient with refractory intestinal Behçet's disease who experienced treatment failure with prior biologic agents. This case sheds light on managing this complex scenario with Janus kinase (JAK) inhibitors, the patient achieved mucosal healing after switching to Upadacitinib. Conclusion: This case underscores the potential of Upadacitinib as an effective alternative for managing difficult cases of intestinal Behçet's disease.

Indexed as

Behcet SyndromeTumor Necrosis Factor-alphaAdultHeterocyclic Compounds, 3-RingHumansIntestinal DiseasesJanus Kinase InhibitorsMaleRemission InductionTreatment OutcomeTumor Necrosis Factor InhibitorsHeterocyclic Compounds, 3-RingJanus Kinase InhibitorsTumor Necrosis Factor-alphaTumor Necrosis Factor Inhibitorsupadacitinibanti-TNF-refractorycase reportintestinal Behçet’s diseasemucosal healingupadacitinib

Identifiers

PMID39582862
PMCPMC11582029

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.